Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)

Time to next treatment or death (TNT-D) may be a patient-relevant endpoint in patients treated with immune checkpoint inhibitors. This study investigate

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Treated With Immune-checkpoint Inhibitors Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Institut Bergonié, Comprehensive Cancer Center

Bordeaux, France

Who can participate

Only the study team can determine whether someone qualifies for participation.

previously untreated advanced melanoma patients.

Treatment and study plan

Nivolumab monotherapy

Drug

nivolumab monotherapy

nivolumab plus ipilimumab

Drug

nivolumab plus ipilimumab

Primary outcomes

Correlation Between Time to Next Treatment or Death (TNT-D) and Overall Survival (OS)

Time frame: 4 years after the start of treatment

Correlation between Time to next treatment or death (TNT-D) and overall survival (OS) in previously untreated advanced melanoma patients.

Sponsors and collaborators

Lead sponsor

Institut Bergonié

Other

Collaborators

Institut National de la Santé Et de la Recherche Médicale, France

Registry information

Official study title

Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials

Acronym: SURROGATE-ICI

Important dates

Study start: 2017
Primary completion: 2020
Study completion: 2020
First posted: May 24, 2019
Registry last updated: Oct 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed